Ziccum Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Ann Gidner

Chief executive officer

kr1.7m

Total compensation

CEO salary percentage	60.1%
CEO tenure	2yrs
CEO ownership	0.9%
Management average tenure	1.3yrs
Board average tenure	4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ann Gidner's remuneration changed compared to Ziccum's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-kr20m
Dec 31 2023	n/a	n/a	-kr21m
Sep 30 2023	n/a	n/a	-kr22m
Jun 30 2023	n/a	n/a	-kr24m
Mar 31 2023	n/a	n/a	-kr27m
Dec 31 2022	kr2m	kr1m	-kr29m

Compensation vs Market: Ann's total compensation ($USD158.20K) is below average for companies of similar size in the Swedish market ($USD252.68K).

Compensation vs Earnings: Insufficient data to compare Ann's compensation with company performance.

CEO

Ann Gidner (57 yo)

2yrs

Tenure

kr1,703,000

Compensation

Ms. Ann Gidner serves as Independent Director at Iconovo AB (publ) since 2021. She had been Chief Executive Officer at Selectimmune Pharma AB (publ) since August 10, 2020 until April 2022. Ms. Gidner serve...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ann Gidner	MD & CEO	2yrs	kr1.70m	0.92% SEK 838.5k
Johny Humaloja	Chief Financial Officer	less than a year	no data	0.028% SEK 25.7k
Xavier Turon	Chief Operating Officer	less than a year	no data	no data
Fabrice Rose	Scientific Director	1.8yrs	no data	0.0065% SEK 5.9k

1.3yrs

Average Tenure

52.5yo

Average Age

Experienced Management: ZICC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Per Gerde	Director	less than a year	no data	1.43% SEK 1.3m
Fredrik Sjovall	Chairman	7.1yrs	no data	0.86% SEK 778.2k
Andreas Rohman	Director	3.1yrs	no data	0.26% SEK 232.9k
Mikaela Bruhammar	Independent Director	5yrs	no data	0.059% SEK 53.3k

4.0yrs

Average Tenure

45yo

Average Age

Experienced Board: ZICC's board of directors are considered experienced (4 years average tenure).

Ziccum Management

Management criteria checks 2/4

Key information

Recent management updates

Ziccum AB (Publ) Appoints Xavier Turon as Chief Operating Officer

MD & CEO recently bought kr159k worth of stock

Ziccum AB (Publ) Appoints Johny Humaloja as CFO, Effective June 15, 2023

Less than half of directors are independent

Ziccum AB (Publ) Elects Per Gerde as Board Member

Chief Executive Officer recently bought kr69k worth of stock

Recent updates

New major risk - Financial position

First quarter 2024 earnings released: kr0.26 loss per share (vs kr0.35 loss in 1Q 2023)

New minor risk - Shareholder dilution

Ziccum AB (publ) to Report Q1, 2024 Results on Apr 29, 2024

Ziccum AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 4.232123 million.

Ziccum AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 4.232123 million.

Ziccum Reports Successful Mrna/Lnp Feasibility Study with Major Biotech Corporation

Ziccum AB (publ) to Report Fiscal Year 2023 Results on Jan 26, 2024

Ziccum AB (Publ) Appoints Xavier Turon as Chief Operating Officer

MD & CEO recently bought kr159k worth of stock

Ziccum AB (publ) Joint Proposal Not Selected for Detailed Application in Current CEPI Call

Ziccum AB (Publ) Appoints Johny Humaloja as CFO, Effective June 15, 2023

Less than half of directors are independent

Ziccum AB (Publ) Elects Per Gerde as Board Member

Chief Executive Officer recently bought kr69k worth of stock

Ziccum AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

ZICCUM AB (publ) Generates Proof of Successful Drying of Lipid Nanoparticles in mRNA Project

Ziccum AB (Publ) Receives Results from Evaluation Study with Pharmaceutical Corporation

Ziccum Appoints Fabrice Rose as New Scientific Director

High number of new directors

High number of new directors

Ziccum AB (publ) Appoints Ann Gidner as Chief Executive Officer

Ziccum AB (publ) to Report Q2, 2022 Results on Aug 23, 2022

Ziccum AB (Publ) Produces Proof of Concept Data in Four Major Covid-19 Vaccine Platforms

New 90-day low: kr22.10

Full year 2020 earnings released: kr2.06 loss per share (vs kr1.45 loss in FY 2019)

New 90-day low: kr23.80

Ziccum AB (Publ) Extends Evaluation Agreement with Janssen Vaccines & Prevention

New 90-day high: kr31.90

Ziccum Takes Lead on New Pilot Study of Vaccine Plant Producing Cost-Effective Thermostable Vaccines At Volume with KeyPlants as Engineering Partner

Ziccum AB (publ) to Report Q3, 2020 Results on Nov 06, 2020

Earnings released

New 90-day high - kr24.70

An undisclosed buyer acquired an unknown stake in Ziccum AB (publ) (NGM:ZICC) from Inhalation Sciences Sweden AB (publ) (NGM:ISAB) for approximately SEK 21.2 million.

Ziccum AB (publ) to Report Q2, 2020 Results on Aug 20, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age